Company Performance Metrics
- Raphael Giami: CEOPast Role: Trialog Clinical Trials, Director Innovation and Business Strategy
- Boaz Lerner: CSO
Panacea-ml revolutionizes clinical trial design with its data-driven, explainable-AI SaaS platform. Our cutting-edge technology addresses the primary causes of clinical development failure by identifying patient profiles that maximize therapeutic efficacy, minimize safety risks, and improve participant retention. Leveraging historical clinical
trials and millions real-world patient health records, Panacea-ml's AI model enhances patient selection criteria, reduces cohort sizes, and uncovers novel marker-endpoint interrelations, surrogate markers, and causal relationships beyond simple statistical correlations.
Our platform is a game-changer for the pharmaceutical industry, facilitating seamless collaboration across drug development, data science, and clinical teams. It accelerates drug development by generating precise sub-population profiles, refining patient selection criteria, and providing informed go/no-go decisions for each phase of development. Panacea-ml is versatile, supporting small sample sizes and various therapeutic domains, including rare diseases and early development stages.
At Panacea-ml, we believe in empowering innovation and fostering collaboration to drive impactful outcomes. Our mission is to shorten time to market and enable early access to innovative treatments for patients worldwide.